ArticleAnnals of the rheumatic diseases2022

Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier.

James R Seibold et al.PubMed ↗Publisher ↗

No numbers read from the abstract.